1. Document reveals scope of Operation Warp Speed and underscores vast military involvement — New data bolsters Sarepta gene therapies for two deadly muscle diseases — Inovio forced to delay planned phase 2/3 testing of COVID vaccine — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Tax benefits lift Mylan’s quarterly profit

Discussion in 'Mylan/Bertek' started by anonymous, May 9, 2018 at 10:53 AM.

  1. anonymous

    anonymous Guest

    Mylan reported yet another quarter of declining sales, a trend the company has been seeing for the last couple of quarters.
    The sales decline was marred by increased competition and the continuing declining sales of the company’s allergy drug EpiPen, which in turn resulted in a 19% decline in sales in its North America sales.
    Revenue declined 1.2% to $2.68 billion from $2.71 billion a year ago.
    Mylan reported a profit increase of 31% for the quarter to $87.1 million or $0.17 per share, mainly influenced by an income tax benefit of $76.6 million.
    On an adjusted basis, the drug maker reported a 3.22% increase in its earnings per share to $0.96.
    https://news.alphastreet.com/mylan-1q-2018-results/
     

  2. anonymous

    anonymous Guest

    even as the CEO continues to get her big bonuses